Isolation and in-silico approach of Modified Embelin derivative from Embelia ribes fruits as anti‐Alzheimer agent

Abstract

Embelin is one of the primary compounds present in the Embelia ribes fruit. Embelin has a broader pharmacological activity such as Anti-inflammatory, anti-bacterial, antioxidant, and many more. The ultimate aim of the study is to ensure the impact of reduced embelin in the management of Alzheimer’s disease. Embelin was isolated and modified by the reduction method, and the Modified Embelin derivative (MED) 3-Undecylcyclohexa-2,5-diene-1,2,4,5-tetraol was analysed through FT-IR, NMR, and Mass Spectroscopic techniques. MED was docked against acetylcholinesterase (AChE) amyloid beta (Aβ) receptors PDB ID: 1EVE & 1B68, respectively. The docking scores remain similar to that of positive standards galantamine and Donepezil.

Graphical Abstract

Keywords:

• Embelin
• Embelia ribes
• molecular docking
• pharmacokinetic parameters
• Alzheimer’s disease

Acknowledgments

We would like to thank SRM Institute of science and Technology for their constant support.

Authors’ contributions

All authors contributed equally to this study. Material preparation, data collection, and analysis were performed by R.R, R.M. K. and S.S All authors read and approved the final manuscript. R.M.K & S.S conceived and designed the experiments.

Disclosure statement

The authors have no relevant financial or non-financial interests to disclose.

Data availability statement

All data generated or analysed during this study included as a supplementary files.

Additional information

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.